# US 2013/0157973 A1 · Pharmaceutical compositions and methods for treating gastrointestinal infections and disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157973 A1
- Document ID: US20130157973A1
- Status: Published application
- Kind: A1
- Application number: 13/720,968
- Filed: 2012-12-19
- Published: 2013-06-20
- Earliest claimed: 2011-12-20
- Assignees: Gilead Sciences, Inc.
- Inventors: Uri Aryeh Lopatin; Daniel B. Tumas
- Web page: https://patentgrep.com/patent/US20130157973A1

## CPC

- C07D 475/06: with a nitrogen atom directly attached in position 4
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/52: Purines, e.g. adenine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 33/00: Antiparasitic agents
- A61P 33/04: Amoebicides
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 473/18: one oxygen and one nitrogen atom, e.g. guanine
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods of treating gastrointestinal disorders, in a patient in need thereof, including disorders of the liver and pancreas, using an amount of an orally dosed TLR-7 compound in an amount sufficient to increase IFN in the gastrointestinal area, including the liver, but not significantly increasing systemic IFN.

## Claims

### Claim 1

A method of treating a gastrointestinal disorder in a human patient in need thereof, comprising administering to the patient an orally administered amount of a TLR agonist sufficient to provide modified IFN expression in the gastrointestinal area, but in an amount less than sufficient to significantly alter systemic IFN.

### Claim 2 (depends on 1)

The method of claim 1 wherein the TLR agonist is:
6-amino-2-butoxy-9-(3-(pyrrolidin-1-ylmethyl)benzyl)-9H-purin-8-ol ; or
4-amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one;

### Claim 3 (depends on 1)

The method of claim 1 wherein the gastrointestinal disorder is cancer or a pathogen infection.

### Claim 4 (depends on 3)

The method of claim 3 wherein the cancer is hepatocellular cancer, colorectal cancer, gastrinoma, insulinoma, glucagonoma, pancreatic ductal adenocarcinoma, VIPoma, somatostatinoma, ACTHoma, adenocarcinoma of the stomach, leiomyosarcoma or adenomatous polyposis.

### Claim 5 (depends on 3)

The method of claim 3 wherein the pathogen infection is a parasitic infection.

### Claim 6 (depends on 5)

The method of claim 5 wherein the parasitic infection is: Clonorchis sinensis, Opisthorchis felineus, Opisthorchis viverrini, Dicrocoelium dendriticum, Elaeophora elaphi, Fasciola, Plasmodium, Amoebiasis, Pseudosuccinea columella, Schistosoma mansoni, Visceral leishmaniasis, Histomonas meleagridis, Histomoniasis, Echinococcus multilocularis, Fasciolosis, Schistosomiasis, Capillaria hepatica, Prosthogonimidae, Alveolar hydatid disease, Clonorchiasis, Toxoplasmosis or Opisthorchiasis.

### Claim 7 (depends on 3)

The method of claim 3 wherein the pathogen infection is a fungal infection.

### Claim 8 (depends on 7)

The method of claim 7 wherein the fungal infection is histoplasmosis, coccidiodomycosis, North American blastomycosis or cryptococcosis.

### Claim 9 (depends on 3)

The method of claim 3 wherein the pathogen infection is a bacterial infection.

### Claim 10 (depends on 3)

The method of claim 3 wherein the pathogen infection is a viral infection.

### Claim 11 (depends on 10)

The method of claim 10 wherein the viral infection is hepatitis B.

### Claim 12 (depends on 10)

The method of claim 10 wherein the viral infection is hepatitis C.

### Claim 13 (depends on 10)

The method of claim 10 wherein the viral infection is HIV.

### Claim 14 (depends on 1)

The method of claim 1 wherein the gastrointestinal disorder is a food allergy.

### Claim 15 (depends on 14)

The method of claim 14 wherein the food allergy is a peanut allergy.

### Claim 16 (depends on 1)

The method of claim 1 wherein the gastrointestinal disorder is an autoimmune disorder.

### Claim 17 (depends on 16)

The method of claim 16 wherein the autoimmune disorder is Crohn's disease.

### Claim 18 (depends on 2)

The method of claim 2 wherein the TLR agonist is:
6-amino-2-butoxy-9-(3-(pyrrolidin-1-ylmethyl)benzyl)-9H-purin-8-ol

### Claim 19 (depends on 2)

The method of claim 2 wherein the TLR agonist is

### Claim 20 (depends on 19)

The method of claim 19, wherein said TLR agonist is used in combination with another active pharmaceutical ingredient.

### Claim 21 (depends on 11)

The method of claim 11 wherein the TLR agonist is:
Compound B.

### Claim 22 (depends on 21)

The method of claim 21 wherein compound B is administered to a patient in need thereof, in a total dose of less than 12 mg twice per week.

### Claim 23 (depends on 21)

The method of claim 21 wherein compound B is administered once or twice per week.

### Claim 24 (depends on 23)

The method of claim 23 wherein compound B is administered once per week.

### Claim 25 (depends on 22)

The method of claim 22 wherein compound B is administered in combination with a nucleoside reverse transcriptase inhibitor; a non-nucleoside reverse transcriptase inhibitor; a protease inhibitor; a cyclophilin inhibitors; immune modulators; or a combination thereof.

### Claim 26 (depends on 22)

The method of claim 22 wherein compound B is administered in combination with a product selected from: etbecavir, telbivudine, lamisvudine, adofovir dipivoxil, entecavir, tenofovir disoproxil fumarate, emtricitabine, tenofovir dipivoxil or its salts and co-crystals; or a yeast-based therapeutic vaccination; or combinations thereof.

### Claim 27

A kit comprising an oral dosage form pharmaceutical composition of compound B, in a package adapted for distribution of said oral dosage form pharmaceutical composition in an amount between 0.5 mg and 12 mg. once per week.
